Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor

Pharmaceutical Research

Volumn 17, Issue 3, 2000, Pages 266-274

  Coloma, M Josephina ^a   Lee, Hwa Jeong ^a   Kurihara, Atsushi ^a   Landaw, Elliot M ^a   Boado, Ruben J ^a   Morrison, Sherie L ^a   Pardridge, William M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

BBB; Blood brain barrier; Drug delivery; Drug targeting; Human insulin receptor

Indexed keywords

INDIUM 111; INSULIN RECEPTOR; INSULIN RECEPTOR ANTIBODY; IODINE 125; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 83 14; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; CHIMERA; DRUG DELIVERY SYSTEM; DRUG TARGETING; GENETIC ENGINEERING; HUMAN; NONHUMAN; PRIMATE; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOOD-BRAIN BARRIER; BRAIN; BRAIN CHEMISTRY; CAPILLARIES; CHELATING AGENTS; CHO CELLS; CRICETINAE; DRUG DELIVERY SYSTEMS; HUMANS; HYBRIDOMAS; INDIUM RADIOISOTOPES; INJECTIONS, INTRAVENOUS; MACACA MULATTA; MICE; PENTETIC ACID; RADIOLIGAND ASSAY; RECEPTOR, INSULIN; RECOMBINANT FUSION PROTEINS;

EID: 0033996507     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007592720793     Document Type: Article

References (30)

1. 1. W. M. Pardridge. CNS drug design based on principles of blood-brain barrier transport. J. Neurochem. 70:1781-1792 (1998).
2. 2. W. M. Pardridge. Vector-mediated drug delivery to the brain. Adv. Drug Del. Rev. 36:299-321 (1999).
3. 3. W. M. Pardridge, J. Eisenberg, and Y. Yang. Human blood-brain barrier insulin receptor. J. Neurochem. 44:1771-1778 (1985).
4. 4. K. R. Duffy and W. M. Pardridge. Blood-brain barrier transcytosis of insulin in developing rabbits. Brain Res. 420:32-38 (1987).
5. 5. W. M. Pardridge, J. Eisenberg, and J. Yang. Human blood-brain barrier transferrin receptor. Metabolism 36:892-895 (1987).
6. 6. J. B. Fishman, J. B. Rubin, J. V. Handrahan, J. R. Connor, and R. E. Fine, Receptor-mediated transcytosis of transferrin across the blood-brain barrier. J. Neurosci. Res. 18:299-304 (1987).
7. 7. K. R. Duffy, W. M. Pardridge, and R. G. Rosenfeld, Human blood-brain barrier insulin-like growth factor receptor. Metabolism 37:136-140 (1988).
8. 8. R. R. Reinhardt and C. A. Bondy, Insulin-like growth factors cross the blood-brain barrier. Endocrinology 135:1753-1761 (1994).
9. 9. P. L. Golden, T. J. Maccagnan, and W. M. Pardridge, Human blood-brain barrier leptin receptor. Binding and endocytosis in isolated human brain microvessels. J. Clin. Invest. 99:14-18 (1997).
10. 10. S. A. Prigent, K. K. Stanley, and K. Siddle. Identification of epitopes on the human insulin receptor reacting with rabbit polyclonal antisera and mouse monoclonal antibodies. J. Biol. Chem. 265:9970-9977 (1990).
11. 11. W. M. Pardridge, Y.-S. Kang, J. L. Buciak, and J. Yang. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm. Res. 12:807-816 (1995).
12. 12. D. Wu, J. Yang, and W. M. Pardridge. Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor. J. Clin. Invest. 100:1804-1812 (1997).
13. 111In chelation, conjugation to a blood-brain barrier delivery vector via a biotin-polyethylene linker, pharmacokinetics, and in vivo imaging of experimental brain tumors. Bioconj. Chem. 10:502-511 (1999).
14. 14. D. Wu and W. M. Pardridge. CNS pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analogue coupled to a blood-brain barrier drug delivery system. J. Pharmacol. Exp. Ther. 279:77-83 (1996).
15. 15. D. Wu and W. M. Pardridge. Neuroprotection with non-invasive neurotrophin delivery to brain. Proc. Natl. Acad. Sci. USA 96:254-259 (1999).
16. 16. S. L. Morrison, M. J. Johnson, L. A. Herzenberg, and V. T. Oi. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. USA 81:6851-6855 (1984).
17. 17. S. L. Morrison, S. Canfield, S. Porter, L. K. Tan, M. Tao, and L. A. Wims. Production and characterization of genetically engineered antibody molecules. Clin. Chem. 34:1668-1675 (1988).
18. 18. P. Chomczynski and N. Sacchi. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-164 (1987).
19. 19. M. J. Coloma, A. Hastings, L. A. Wims, and S. L. Morrison. Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction. J. Immunol. Meth. 159:89-104 (1992).
20. 20. L. Cosgrove, G. O. Lovrecz, A. Verkuylen, L. Cavaleri, L. A. Black, J. D. Bentley, G. J. Howlett, P. P. Gray, C. W. Ward, and N. M. McKern. Purification and properties of insulin receptor ectodomain from large-scale mammalian cell culture. Protein Expression Purification 6:789-798 (1995).
21. 21. U. Bickel, V. M. Y. Lee, J. Q. Trojanowski, and W. M. Pardridge. Development and in vitro characterization of a cationized monoclonal antibody against βA4 protein: A potential probe for Alzheimer's disease. Bioconj. Chem. 5:119-125 (1994).
22. 22. W. J. Dixon, ed. BMDP Statistical Software Manual, University of California Press, Berkeley, pp. 921-958 (1990).
23. 23. P. J. Munson and P. Rodbard. LIGAND: A versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem. 107:220-239 (1980).
24. 24. J. T. Hjelle, J. Baird-Lambert, G. Cardinale, S. Spector, and S. Udenfriend. Isolated microvessels: the blood-brain barrier in vitro. Proc. Natl. Acad. Sci. USA 75:4544-4548 (1978).
25. 25. M. Gibaldi, and D. Perrier. Pharmacokinetics. Marcel Dekker, Inc., New York (1982).
26. 26. D. R. Swindler and J. Erwin, editors. Comparative Primate Biology. Alan R. Liss, Inc., New York, Vol. 1 (Systematics, Evolution, Anatomy) (1986).
27. 27. Y. S. Kang and W. M. Pardridge. Use of neutral-avidin improves pharmacokinetics and brain delivery of biotin bound to an avidin-monoclonal antibody conjugate. J. Pharmacol. Exp. Ther. 269:791-796 (1994).
28. 28. A. F. LoBuglio, R. H. Wheeler, J. Trang, A. Haynes, K. Rogers, E. B. Harvey, L. Sun, J. Ghrayeb, and M. B. Khazaeli. Mouse/ human chimeric monoclonal antibody in man: Kinetics and immune response. Proc. Natl. Acad. Sci. USA 86:4220-4224 (1989).
29. 29. J. Y. Li, K. Sugimura, R. J. Boado, H. J. Lee, C. Zhang, S. Dubel, and W. M. Pardridge. Genetically engineered brain drug delivery vectors - cloning, expression, and in vivo application of an anti-transferrin receptor single chain antibody-streptavidin fusion gene and protein. Protein Engineering 12:787-796 (1999).
30. 30. M. L. Penichet, Y. S. Kang, W. M. Pardridge, S. L. Morrison, and S. U. Shin. An anti-transferrin receptor antibody-avidin fusion protein serves as a delivery vehicle for effective brain targeting in an animal model. Initial applications in antisense drug delivery to the brain. J. Immunol. 163:4421-4426 (1999).